BERWYN, PA — Nordic Pharma, Inc., a subsidiary of the international healthcare company Nordic Group B.V., has announced the latest addition to its U.S. Medical Advisory Board (MAB)—John P. Fezza, MD, a renowned oculoplastic surgeon. This strategic appointment comes as the company gears up for the launch of LACRIFILL® Canalicular Gel, a pioneering treatment for Dry Eye Disease.
Dr. Fezza joins an illustrious group of eye care professionals on the MAB, including leaders from both ophthalmology and optometry. The board plays a critical role in guiding Nordic Pharma’s strategies, especially as it prepares to introduce LACRIFILL, a novel therapy that utilizes a cross-linked hyaluronic acid derivative designed to temporarily block tear drainage through the occlusion of the canalicular system.
Eric Donnenfeld, MD, Chair of the MAB, expressed his enthusiasm for Dr. Fezza’s joining, highlighting the unique perspective and expertise he brings to the treatment of dry eye disease. Dr. Fezza, credited as the inventor of LACRIFILL Canalicular Gel, shared his excitement about the collaboration and the potential impact of this innovative product on dry eye treatment.
The U.S. Medical Advisory Board of Nordic Pharma comprises a diverse and distinguished panel of experts from across the country. Their collective experience and insight are set to play a pivotal role in the successful launch of LACRIFILL Canalicular Gel. Philip Gioia, President of the U.S. team at Nordic Pharma, underscored the significance of Dr. Fezza’s contributions to the board and the launch strategy for LACRIFILL.
In addition to the advisory board update, Nordic Pharma is enhancing its commercial strategy with the appointment of Todd Love as National Sales Director by Inizio Engage. With a rich history in the eye care industry, including significant tenures at Alcon and Bausch & Lomb, Love is poised to lead the sales initiatives for LACRIFILL Canalicular Gel, leveraging his extensive experience and leadership skills.
The introduction of LACRIFILL Canalicular Gel represents a significant advancement in the management of dry eye disease, offering a new approach to treatment that promises to benefit millions of patients. With the support of its expanded Medical Advisory Board and strengthened sales leadership, Nordic Pharma is well-positioned to make a meaningful impact in the eye care community.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.